Products & Innovation / REYOBIQ™

REYOBIQ™

REYOBIQ™ (rhenium Re 186 obisbemeda) is an investigational radiotherapeutic for central nervous system (CNS) cancers, the first to pair the radioisotope rhenium-186 with a nanoliposome delivery vehicle. It is being studied in recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer, designed to deliver a concentrated dose of radiation directly to the disease.

A dose that stays where it’s placed.

What sets REYOBIQ™ apart is how it’s designed to keep its dose at the tumor. Here is what it is, and how it’s intended to deliver.

REYOBIQ™ pairs a radioactive isotope with a delivery vehicle, being studied so the dose stays where it’s placed.

The isotope.

Rhenium-186, a radioactive isotope, whose beta energy is intended to travel only a millimeter or two, concentrating dose on the tumor while limiting exposure to healthy tissue nearby.

The delivery vehicle.

A nanoliposome that encapsulates the isotope, designed to keep it at the delivery site and improve how it distributes through tumor tissue.

A dose you can see.

The isotope’s gamma energy is imageable, so where the dose goes will be seen rather than assumed.

REYOBIQ™ is administered directly into the central nervous system compartment where the disease sits, in a clinical trial setting.

Into brain tissue.

For tumors in the brain, a catheter is placed at the tumor and the therapy is infused under positive pressure. This is convection-enhanced delivery, which moves the therapy through interstitial tissue rather than relying on diffusion alone.

Into the cerebrospinal fluid.

For leptomeningeal metastases, the therapy is given into the ventricles through an Ommaya reservoir, reaching disease that has spread into the cerebrospinal fluid.

Imaged as it goes.

Distribution is imaged partway through the infusion, again at the end, and at intervals afterward, so delivery is confirmed rather than assumed.

Man in a pink button-down shirt speaking during an interview in a bright, modern lounge.

How REYOBIQ™ fits into the platform.

Hear from Cerenome’s President and CEO on how REYOBIQ™ is integral to the platform, and why targeted radiotherapy matters for these cancers.

What the Phase 1 data shows.

REYOBIQ™ has been evaluated in a multicenter, single-arm Phase 1 trial in recurrent glioblastoma, with results published in Nature Communications in 2025.1 It remains investigational and is available only through a clinical trial.

Published.

Phase 1 results in recurrent glioblastoma, Nature Communications (Brenner et al, 2025).

Presented.

ReSPECT-LM data, SNO Annual Conference (2026).

Measured.

Tumor absorbed dose was quantified by imaging in each patient dosed, rather than estimated.

1. Brenner AJ, et al. Convection enhanced delivery of rhenium (186Re) obisbemeda (186RNL) in recurrent glioma: a multicenter, single arm, phase 1 clinical trial. Nat Commun. 2025. doi:10.1038/s41467-025-57263-1.

Where REYOBIQ™ stands.

REYOBIQ™ is advancing through clinical development, with regulatory recognition and non-dilutive backing along the way.

Regulatory designations.

U.S. FDA has granted REYOBIQ™ five regulatory designations: Orphan Drug Designation for glioblastoma; Orphan Drug Designation for leptomeningeal metastases in breast cancer and lung cancer patients; and Fast Track Designation for leptomeningeal metastases and recurrent glioblastoma.

Non-dilutive funding.

ReSPECT-LM is backed by a $17.6M CPRIT grant, ReSPECT-GBM by a $3.3M National Cancer Institute award, and ReSPECT-PBC by a $3M U.S. Department of Defense grant.

In active trials.

Three ReSPECT™ trials are active and moving towards pivotal trials, across recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer.

How REYOBIQ™ fits the platform.

In leptomeningeal metastases, CNSide® and investigational REYOBIQ™ operate within the same cerebrospinal-fluid compartment—creating the potential to connect diagnostic, molecular, and treatment-response data as Cerenome develops its broader data capabilities.